Silver Nitrate Vs. Triamcinolone for Treatment of Hypergranulation Tissue
Launched by FRANCESCO EGRO · Nov 6, 2024
Trial Information
Current as of May 03, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how effective two different treatments—silver nitrate and triamcinolone—are for helping wounds that have hypergranulation tissue, which is extra tissue that forms as a wound heals. The study will take place over four years at UPMC Mercy and will involve patients with traumatic wounds that show this condition. Participants will be randomly assigned to receive either silver nitrate, triamcinolone, or both treatments one after the other. The goal is to find out which treatment works best in reducing or eliminating the hypergranulation tissue.
To be eligible for this trial, participants must be at least 18 years old and have non-infected traumatic wounds with hypergranulation tissue. They will also need to agree to take part in the study. However, people with known allergies to the treatments, those with wounds that don’t show hypergranulation, or those with complex or infected wounds won’t be able to participate. If you join the study, you can expect regular check-ins to monitor how your wound responds to the treatment. This research aims to improve care strategies for patients dealing with similar wound healing issues.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients must be 18 years or older.
- • Patients must be admitted to the institution with non-infected, traumatic wounds exhibiting hypergranulation tissue.
- • Patients must provide consent to participate in the study.
- • Eligible wounds include superficial or partial-thickness wounds.
- • Wounds will be categorized based on size and depth, with variations controlled for in the statistical analysis.
- Exclusion Criteria:
- • Patients with known allergies or contraindications to silver nitrate or triamcinolone.
- • Patients with wounds that do not exhibit hypergranulation tissue.
- • Patients with wounds not primarily due to traumatic injury (e.g., surgical wounds, pressure ulcers).
- • Full-thickness, infected, or complex wounds will be excluded, as these may require different management strategies.
About Francesco Egro
Francesco Egro is a dedicated clinical trial sponsor focused on advancing medical research and innovation through rigorous and ethical clinical studies. With a commitment to improving patient outcomes, the organization collaborates with leading healthcare institutions and professionals to facilitate the development of novel therapies and interventions. Leveraging a deep understanding of regulatory frameworks and clinical methodologies, Francesco Egro ensures that all trials are conducted with the highest standards of integrity, safety, and scientific excellence, ultimately contributing to the enhancement of global health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pittsburgh, Pennsylvania, United States
Patients applied
Trial Officials
Francesco M Egro, MD, MSc, MRCS
Principal Investigator
Department of Plastic Surgery, University of Pittsburgh Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported